Ionsys

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
06-11-2018
Ciri produk Ciri produk (SPC)
06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
06-11-2018

Bahan aktif:

fentanyl hydrochloride

Boleh didapati daripada:

Incline Therapeutics Europe Ltd

Kod ATC:

N02AB03

INN (Nama Antarabangsa):

fentanyl

Kumpulan terapeutik:

Analgesics

Kawasan terapeutik:

Pain, Postoperative

Tanda-tanda terapeutik:

Ionsys is indicated for the management of acute moderate to severe post-operative pain in adult patients.

Ringkasan produk:

Revision: 2

Status kebenaran:

Withdrawn

Tarikh kebenaran:

2015-11-18

Risalah maklumat

                                28
B. PACKAGE LEAFLET
Medicinal product no longer authorised
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
IONSYS 40 MICROGRAMS PER DOSE TRANSDERMAL SYSTEM
FENTANYL
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, please ask your doctor or your
nurse.
•
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even if
their symptoms are the same as yours.
•
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What IONSYS is and what it is used for
2.
Before you use IONSYS
3.
How to use IONSYS
4.
Possible side effects
5.
How to store IONSYS
6.
Contents of the pack and other information
1.
WHAT IONSYS IS AND WHAT IT IS USED FOR
What IONSYS is
IONSYS is a transdermal system (to be applied on intact skin) that
contains a strong analgesic (pain
reliever) medicine called fentanyl.
What IONSYS is used for
IONSYS is used to treat short-term moderate to severe pain in adults
after an operation. IONSYS is
used in hospital only.
How IONSYS works
IONSYS is a small device applied to the skin of your upper arm or
chest. It works by delivering
fentanyl through your skin to relieve your pain.
You must talk to a doctor if you do not feel better or if you feel
worse.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE IONSYS
DO NOT USE IONSYS:
•
if you are allergic
(hypersensitive)
_ _
to fentanyl, or any of the other ingredients of IONSYS (listed
in section 6).
•
if you suffer from severe breathing problems or cystic fibrosis.
WARNINGS AND PRECAUTIONS
Talk to your doctor or nurse before using IONSYS if:
•
you have a severe or persistent lung disease, or any breathing
problems
•
you have a very slow heart rate, low blood pressure, or other serious
heart problem
•
you have problems with your liver or kidneys
•
you ha
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
IONSYS 40 micrograms per dose transdermal system
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each IONSYS system contains fentanyl hydrochloride equivalent to 9.7
mg of fentanyl and delivers
40 micrograms fentanyl per dose, to a maximum of 80 doses (3.2 mg/24
hours).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Transdermal system
IONSYS is composed of an electronic controller and a drug unit with
two hydrogels. The controller is
white with the identifier ‘IONSYS
®’
and has
a digital display, a light window, and a recessed dose
activation button. The drug unit is blue on the side that connects to
the controller and has a red bottom
housing containing the hydrogels, one of which contains the fentanyl.
The assembled IONSYS
product measures 47 mm x 75 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
IONSYS is indicated for the management of acute moderate to severe
post-operative pain in adult
patients.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
IONSYS is restricted to hospital use only. Treatment should be
initiated by and remain under the
guidance of a physician experienced in the management of opioid
therapy. Due to the well-known
potential of abuse of fentanyl, physicians should evaluate patients
for a history of drug abuse (see
section 4.4).
Posology
Patients should be titrated to an acceptable level of analgesia prior
to initiating use of IONSYS (see
section 5.1).
IONSYS should only be activated by the patient.
Each dose of IONSYS delivers 40 micrograms of fentanyl over a 10
minute period, to a maximum of
240 micrograms per hour (6 doses each of 10 minutes duration). IONSYS
will operate for 24 hours
after the system is assembled or for 80 doses, whichever comes first,
and then becomes inoperative.
After 24 hours or 80 doses, a new system should be applied if
necessary. Each new system should be
placed on a new skin site. With each new IONSYS application
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 06-11-2018
Ciri produk Ciri produk Bulgaria 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 06-11-2018
Risalah maklumat Risalah maklumat Sepanyol 06-11-2018
Ciri produk Ciri produk Sepanyol 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 06-11-2018
Risalah maklumat Risalah maklumat Czech 06-11-2018
Ciri produk Ciri produk Czech 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Czech 06-11-2018
Risalah maklumat Risalah maklumat Denmark 06-11-2018
Ciri produk Ciri produk Denmark 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 06-11-2018
Risalah maklumat Risalah maklumat Jerman 06-11-2018
Ciri produk Ciri produk Jerman 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 06-11-2018
Risalah maklumat Risalah maklumat Estonia 06-11-2018
Ciri produk Ciri produk Estonia 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 06-11-2018
Risalah maklumat Risalah maklumat Greek 06-11-2018
Ciri produk Ciri produk Greek 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Greek 06-11-2018
Risalah maklumat Risalah maklumat Perancis 06-11-2018
Ciri produk Ciri produk Perancis 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 06-11-2018
Risalah maklumat Risalah maklumat Itali 06-11-2018
Ciri produk Ciri produk Itali 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Itali 06-11-2018
Risalah maklumat Risalah maklumat Latvia 06-11-2018
Ciri produk Ciri produk Latvia 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 06-11-2018
Risalah maklumat Risalah maklumat Lithuania 06-11-2018
Ciri produk Ciri produk Lithuania 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 06-11-2018
Risalah maklumat Risalah maklumat Hungary 06-11-2018
Ciri produk Ciri produk Hungary 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 06-11-2018
Risalah maklumat Risalah maklumat Malta 06-11-2018
Ciri produk Ciri produk Malta 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Malta 06-11-2018
Risalah maklumat Risalah maklumat Belanda 06-11-2018
Ciri produk Ciri produk Belanda 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 06-11-2018
Risalah maklumat Risalah maklumat Poland 06-11-2018
Ciri produk Ciri produk Poland 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Poland 06-11-2018
Risalah maklumat Risalah maklumat Portugis 06-11-2018
Ciri produk Ciri produk Portugis 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 06-11-2018
Risalah maklumat Risalah maklumat Romania 06-11-2018
Ciri produk Ciri produk Romania 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Romania 06-11-2018
Risalah maklumat Risalah maklumat Slovak 06-11-2018
Ciri produk Ciri produk Slovak 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 06-11-2018
Risalah maklumat Risalah maklumat Slovenia 06-11-2018
Ciri produk Ciri produk Slovenia 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 06-11-2018
Risalah maklumat Risalah maklumat Finland 06-11-2018
Ciri produk Ciri produk Finland 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Finland 06-11-2018
Risalah maklumat Risalah maklumat Sweden 06-11-2018
Ciri produk Ciri produk Sweden 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 06-11-2018
Risalah maklumat Risalah maklumat Norway 06-11-2018
Ciri produk Ciri produk Norway 06-11-2018
Risalah maklumat Risalah maklumat Iceland 06-11-2018
Ciri produk Ciri produk Iceland 06-11-2018
Risalah maklumat Risalah maklumat Croat 06-11-2018
Ciri produk Ciri produk Croat 06-11-2018
Laporan Penilaian Awam Laporan Penilaian Awam Croat 06-11-2018

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen